Hangzhou-based Sciwind Biosciences Co., Ltd has announced the first subject dosing in a Phase III clinical study for its ecnoglutide (XW003), a novel, long-acting glucagon-like peptide-1 (GLP-1) analog, in adult patients with type 2 diabetes in China. The trial marks a significant milestone in the development of this innovative therapy, which aims to improve treatment options for patients with metabolic diseases.<\/p>\n\n\n\n
Phase III Trial Details<\/strong> The second Phase III trial (NCT05680129) is a multicenter, open-label, randomized study comparing ecnoglutide to dulaglutide in patients with type 2 diabetes inadequately controlled by metformin therapy. Up to 600 participants will be enrolled at approximately 60 sites in China, with treatment lasting 52 weeks followed by a 5-week follow-up period.<\/p>\n\n\n\n Ecnoglutide: Mechanism and Development<\/strong> Sciwind’s Pipeline and Future Outlook<\/strong> Hangzhou-based Sciwind Biosciences Co., Ltd has announced the first subject dosing in a Phase III…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,76,25,822],"class_list":["post-22443","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-diabetes","tag-nash","tag-potential-first-in-class","tag-sciwind-biosciences"],"yoast_head":"\n
The first Phase III trial (NCT05680155) is a multicenter, double-blind, randomized, placebo-controlled study evaluating the efficacy and safety of once-weekly subcutaneous administration of ecnoglutide in approximately 210 treatment-na\u00efve patients with type 2 diabetes. Conducted at approximately 35 sites in China, the trial will treat participants with the study drug for up to 52 weeks, followed by a 5-week follow-up period.<\/p>\n\n\n\n
GLP-1 analogs are effective therapies for managing type 2 diabetes and obesity and have demonstrated potential in treating non-alcoholic steatohepatitis (NASH). Ecnoglutide (XW003) is a novel, long-acting GLP-1 peptide analog optimized for improved biological activity, cost-effective manufacturing, and once-weekly dosing. The molecule has shown significant treatment benefits in Phase I and Phase II clinical studies for patients with type 2 diabetes and obesity. Sciwind plans to initiate a regulatory study for ecnoglutide in obesity in the near term.<\/p>\n\n\n\n
Sciwind is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies for metabolic syndrome. Its pipeline includes potentially first-in-class and best-in-class drug candidates such as ecnoglutide (Phase III), oral GLP-1 peptide analog XW004 (Phase I), and oral small molecule GLP-1 receptor agonist XW014 (Phase I). These developments highlight Sciwind’s commitment to advancing novel treatments for metabolic diseases.<\/a>-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"